ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

Phase 3

Completed

Conditions: Active Rheumatoid Arthritis

Interventions: Drug: CDP870

First Posted Date: 2015-10-26

Last Posted Date: 2015-11-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 86

Registration Number: NCT02586246

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Completed

Conditions: Cardiovascular Disease
Overactive Bladder

Interventions: Drug: Mirabegron

First Posted Date: 2015-10-07

Last Posted Date: 2015-10-07

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 316

Registration Number: NCT02570035

Locations: 🇯🇵
Site JP81007, Chiba, Japan
🇯🇵
Site JP81001, Hokkaido, Japan
🇯🇵
Site JP81025, Hyogo, Japan

and more 25 locations

Bioequivalence Evaluation of a New and Current Tablet of ASP015K

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: peficitinib

First Posted Date: 2015-08-24

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 40

Registration Number: NCT02531191

A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules

Phase 1

Completed

Conditions: Urine Phosphorus Excretion
Healthy

Interventions: Drug: ASP1585

First Posted Date: 2015-08-24

Last Posted Date: 2015-08-24

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 60

Registration Number: NCT02531204

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: ASP1941

First Posted Date: 2015-08-20

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 43

Registration Number: NCT02529449

Locations: 🇯🇵
Site JP00010, Osaka, Japan
🇯🇵
Site JP00002, Fukuoka, Japan
🇯🇵
Site JP00008, Kanagawa, Japan

and more 8 locations

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Phase 1

Completed

Conditions: Chronic Kidney Disease
Hyperphosphatemia Undergoing Hemodialysis

Interventions: Drug: ASP3325

First Posted Date: 2015-07-29

Last Posted Date: 2024-11-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT02510274

Locations: 🇯🇵
Site: 4, Aichi, Japan
🇯🇵
Site: 3, Shizuoka, Japan
🇯🇵
Site: 1, Ibaraki, Japan

and more 2 locations

A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects

Interventions: Drug: ASP3325
Drug: Placebo

First Posted Date: 2015-07-17

Last Posted Date: 2015-07-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 124

Registration Number: NCT02500953

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Phase 2

Terminated

Conditions: EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Interventions: Drug: ASP8273 Capsules
Drug: ASP8273 Capsules A

First Posted Date: 2015-07-17

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 31

Registration Number: NCT02500927

Locations: 🇯🇵
Site: 1, Miyagi, Japan
🇯🇵
Site: 9, Hiroshima, Japan
🇯🇵
Site: 8, Hyogo, Japan

and more 8 locations

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: ipragliflozin

First Posted Date: 2015-06-24

Last Posted Date: 2024-10-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 11412

Registration Number: NCT02479399

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

Phase 1

Completed

Conditions: Cedar Pollinosis

Interventions: Drug: ASP4070
Drug: Placebo

First Posted Date: 2015-06-11

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 66

Registration Number: NCT02469688

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy